Ergoteles’s Veracyte VCYT Stock Holding History

Ergoteles’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-99,796	Closed	-$2.37M	–	1779
2022 Q4	$2.37M	Buy	+99,796	New	+$2.32M	0.09%	234
2021 Q3	–	Sell	-18,000	Closed	-$720K	–	1700
2021 Q2	$720K	Buy	+18,000	New	+$770K	0.02%	632

Other funds holding VCYT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ergoteles's VCYT Position: Q1 2023 in Review

Ergoteles sold out of Veracyte (VCYT) in Q1 2023, closing a stake of 99,796 shares — an estimated $2.37M sold.

Ergoteles first reported a position in VCYT in Q2 2021 and held it in 2 quarters. The position peaked at $2.37M in Q4 2022. 232 funds tracked by Wall St. Rank hold VCYT as of Q1 2023.

Ergoteles reported no remaining Veracyte position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 99,796 Veracyte shares in Q1 2023, an estimated $2.37M.
Ergoteles first reported a position in Veracyte in Q2 2021 and held it in 2 quarters.
Ergoteles's Veracyte position peaked at $2.37M in Q4 2022.
232 funds tracked by Wall St. Rank held Veracyte as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.